ClinicalTrials.gg
CompletedNCT00643383Updated May 1, 2012

A Two-Arm Study Comparing the Analgesic Efficacy and Safety of Acetaminophen and Tramadol Combination BID Versus Placebo for the Treatment of Acute Low Back Pain

A Phase 3 interventional study of Combination drug (Acetaminophen + Tramadol) and Placebo in Acute Low Back Pain, sponsored by Labopharm Inc.. Completed at 38 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2012-05-01.

Sponsored by Labopharm Inc. · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
277
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

A multi-center placebo controlled, double-blind, trial comparing the analgesic efficacy and safety of Acetram Contramid® BID versus placebo for the treatment of acute low back pain in patients between 18 and 80 yrs of age.

02

Conditions studied

  • Acute Low Back Pain
03

In context

Lead sponsor

Labopharm Inc. is the lead sponsor of 19 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females in generally good health aged 18-80 years with moderate to severe acute low back pain.
  • Current acute low back pain episode within 48h prior to study entry.
  • Pain must be moderate to severe following incident

Exclusion criteria

Exclusion Criteria:

  • Chronic low back pain
  • Ongoing or history of alcohol or drug abuse
  • Body Mass Index greater 39
  • Treatment within the last 3 weeks with monoamine oxidase inhibitors; tricyclic antidepressants and other tricyclic compounds; neuroleptics; selective serotonin reuptake inhibitors
  • Known history or symptoms suspicious for cancer
  • Significant renal or liver disease
  • Spinal surgery within 1 year of study entry.
  • Subjects who are pregnant or lactating.
  • Subjects with unstable medical disease.
  • Subjects who have received treatment with an investigational product/device with 30 days prior to study entry.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
277 participants (actual)

Study arms

  • Active comparator
    1

    Drug: Combination drug (Acetaminophen + Tramadol)

  • Placebo comparator
    2

    Drug: Placebo

Interventions

  • DrugCombination drug (Acetaminophen + Tramadol)
  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Pain Intensity change from Baseline

Secondary outcomes

  1. Overall satisfaction with the study medication

  2. Safety evaluation

07

Study locations

38 sites
  • Montgomery, Alabama 36117, United States
  • Centennial, Colorado 80112, United States
  • Hialeah, Florida 33013, United States
  • Largo, Florida 33770, United States
  • New Port Richey, Florida 34652, United States
  • Indianapolis, Indiana 46254, United States
  • Waterloo, Iowa 50702, United States
  • Baton Rouge, Louisiana 70809, United States
  • Brockton, Massachusetts 02301, United States
  • Minneapolis, Minnesota 55415, United States
  • Oklahoma City, Oklahoma 73112, United States
  • Rapid City, South Dakota 57702, United States
  • Crossville, Tennessee 38555, United States
  • Bryan, Texas 77082, United States
  • Dallas, Texas 75235, United States
  • Houston, Texas 77074, United States
  • Salt Lake City, Utah 84109, United States
  • Salt Lake City, Utah 84121, United States
  • Bathurst, New Brunswick E2A4X7, Canada
  • Mount Pearl, Newfoundland and Labrador A1N1W7, Canada
  • Greater Sudbury, Ontario P3E1H5, Canada
  • Newmarket, Ontario L3Y5G8, Canada
  • Newmarket, Ontario L3Y7V1, Canada
  • Sarnia, Ontario N7T4X3, Canada
  • Toronto, Ontario M9V4B4, Canada
  • Toronto, Ontario M9W4L6, Canada
  • Cowansville, Quebec J2K2X9, Canada
  • Drummondville, Quebec J2B7T1, Canada
  • Gatineau, Quebec J9A1K7, Canada
  • Granby, Quebec J2G8Z9, Canada
  • Mirabel, Quebec J7J2K8, Canada
  • Montreal, Quebec H1S3A9, Canada
  • Montreal, Quebec H4N2W2, Canada
  • Pointe-Claire, Quebec H9R4S3, Canada
  • Québec, Quebec G1G4A2, Canada
  • Québec, Quebec G1V4X7, Canada
  • Sherbrooke, Quebec J1H1Z1, Canada
  • Trois-Rivières, Quebec G8T7A1, Canada
08

References and documents

Publications

  • Lasko B, Levitt RJ, Rainsford KD, Bouchard S, Rozova A, Robertson S. Extended-release tramadol/paracetamol in moderate-to-severe pain: a randomized, placebo-controlled study in patients with acute low back pain. Curr Med Res Opin. 2012 May;28(5):847-57. doi: 10.1185/03007995.2012.681035. Epub 2012 Apr 25. PubMed 22458917 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 1, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00643383
Lead sponsor
Labopharm Inc.
Responsible party
Sponsor
First posted
Mar 26, 2008
Start date
Mar 2008
Primary completion
Jan 2009
Completion
Feb 2009
Last update
May 1, 2012
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion